Mechanism of microRNA-223-3p inhibiting hepatic stellate cell activation by targeting microtubule-associated protein 1B

Wentao XIE; Kangkang YU; Qi CHENG; Ning LI

doi:10.3969/j.issn.1001-5256.2023.12.015

Volume 39 Issue 12

Dec. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(12): 2845-2850

PDF( 1203 KB)

Mechanism of microRNA-223-3p inhibiting hepatic stellate cell activation by targeting microtubule-associated protein 1B

DOI: 10.3969/j.issn.1001-5256.2023.12.015

Department of Infectious Diseases，Huashan Hospital，Fudan University；Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response；National Medical Center for Infectious Diseases，Shanghai 200040，China

Research funding:

National Natural Science Fundation of China (8200033704);

National Natural Science Fundation of China (81770565)

More Information

Corresponding author: LI Ning， lining_hs@fudan.edu.cn （ORCID： 0000-0002-4375-2857）
Received Date: 2022-12-09
Accepted Date: 2023-05-19
Published Date: 2023-12-12

Abstract

Abstract

Objective To investigate the effect of microRNA-223-3p （miR-223-3p） on hepatic stellate cell （HSC） activation and its mechanism. Methods Human HSC LX2 cells were selected for the study， and LX2 cells were stimulated by TGF-β to establish a model of HSC activation； quantitative real-time PCR was used to measure the change in the expression level of miR-223-3p during HSC activation. After LX2 cells were transfected with miR-223-3p mimic， quantitative real-time PCR， Western blot， and immunofluorescence assay were used to clarify the regulatory effect of miR-223-3p on HSC activation， and dual-luciferase reporter assay was used to verify the association between miR-223-3p and the target gene MAP1B. After LX2 cells were transfected with MAP1B siRNA， Western blot was used to clarify the influence of inhibiting MAP1B expression on HSC activation； after LX2 cells were transfected with miR-223-3p， quantitative real-time PCR and Western blot were used to verify the regulatory effect of miR-223-3p on MAP1B. The independent-samples t test was used for comparison of continuous data between two groups. Results HSC in the activated state had a significant reduction in the expression level of miR-223-3p compared with those in the resting state （t=9.12， P<0.001）. Overexpression of miR-223-3p inhibited the mRNA and protein expression levels of the markers for HSC activation alpha-smooth muscle actin and collagen type Ⅰ （mRNA expression： t=8.35 and 12.23， both P<0.01； protein expression： t=16.24 and 20.90， both P<0.001）. The dual-luciferase reporter assay confirmed that MAP1B was a potential target gene of miR-223-3p. Compared with the control group， LX2 cells with miR-223-3p overexpression had significant reductions in the mRNA and protein expression levels of MAP1B （mRNA expression： t=5.95， P<0.01； protein expression： t=11.12， P<0.001）. Conclusion This study shows that miR-223-3p can inhibit HSC activation by targeting MAP1B.
- Hepatic Fibrosis,
- Microtubule-Associated Proteins,
- Hepatic Stellate Cells,
- MicroRNAs

FullText(HTML)

References(16)

References

[1]	TRAUTWEIN C, FRIEDMAN SL, SCHUPPAN D, et al. Hepatic fibrosis: Concept to treatment[J]. J Hepatol, 2015, 62( 1 Suppl): S15- S24. DOI: 10.1016/j.jhep.2015.02.039.
[2]	WANG XL, HE Y, MACKOWIAK B, et al. microRNAs as regulators, biomarkers and therapeutic targets in liver diseases[J]. Gut, 2021, 70( 4): 784- 795. DOI: 10.1136/gutjnl-2020-322526.
[3]	BAO SX, ZHENG JM, LI N, et al. Serum microRNA levels as a noninvasive diagnostic biomarker for the early diagnosis of hepatitis B virus-related liver fibrosis[J]. Gut Liver, 2017, 11( 6): 860- 869. DOI: 10.5009/gnl16560.
[4]	TSUCHIDA T, FRIEDMAN SL. Mechanisms of hepatic stellate cell activation[J]. Nat Rev Gastroenterol Hepatol, 2017, 14( 7): 397- 411. DOI: 10.1038/nrgastro.2017.38.
[5]	TRIVEDI P, WANG S, FRIEDMAN SL. The power of plasticity-metabolic regulation of hepatic stellate cells[J]. Cell Metab, 2021, 33( 2): 242- 257. DOI: 10.1016/j.cmet.2020.10.026.
[6]	RODERBUG C, TRAUTWEIN C. Cell-specific functions of miRNA in the liver[J]. J Hepatol, 2017, 66( 3): 655- 656. DOI: 10.1016/j.jhep.2016.09.015.
[7]	HUANG C, ZHENG JM, CHENG Q, et al. Serum microRNA-29 levels correlate with disease progression in patients with chronic hepatitis B virus infection[J]. J Dig Dis, 2014, 15( 11): 614- 621. DOI: 10.1111/1751-2980.12185.
[8]	LAKNER AM, STEUERWALD NM, WALLING TL, et al. Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis[J]. Hepatology, 2012, 56( 1): 300- 310. DOI: 10.1002/hep.25613.
[9]	ZHANG R, LI WH, JIANG XD, et al. Ferulic acid combined with bone marrow mesenchymal stem cells attenuates the activation of hepatic stellate cells and alleviates liver fibrosis[J]. Front Pharmacol, 2022, 13: 863797. DOI: 10.3389/fphar.2022.863797.
[10]	ZHANG J, JIAO JJ, CERMELLI S, et al. miR-21 inhibition reduces liver fibrosis and prevents tumor development by inducing apoptosis of CD24⁺ progenitor cells[J]. Cancer Res, 2015, 75( 9): 1859- 1867. DOI: 10.1158/0008-5472.CAN-14-1254.
[11]	DING RR, ZHENG JM, LI N, et al. DZNep, an inhibitor of the histone methyltransferase EZH2, suppresses hepatic fibrosis through regulating miR-199a-5p/SOCS₇ pathway[J]. PeerJ, 2021, 9: e11374. DOI: 10.7717/peerj.11374.
[12]	OKSUZ Z, SERIN MS, KAPLAN E, et al. Serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers for HCV-positive cirrhosis and hepatocellular carcinoma[J]. Mol Biol Rep, 2015, 42( 3): 713- 720. DOI: 10.1007/s11033-014-3819-9.
[13]	TESSEMA M, YINGLING CM, PICCHI MA, et al. Epigenetic repression of CCDC37 and MAP1B links chronic obstructive pulmonary disease to lung cancer[J]. J Thorac Oncol, 2015, 10( 8): 1181- 1188. DOI: 10.1097/JTO.0000000000000592.
[14]	ARASAKI K, NAGASHIMA H, KUROSAWA Y, et al. MAP1B-LC1 prevents autophagosome formation by linking syntaxin 17 to microtubules[J]. EMBO Rep, 2018, 19( 8): e45584. DOI: 10.15252/embr.201745584.
[15]	HERNANDEZ-GEA V, GHIASSI-NEJAD Z, ROZENFFLD R, et al. Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues[J]. Gastroenterology, 2012, 142( 4): 938- 946. DOI: 10.1053/j.gastro.2011.12.044.
[16]	TUOHETAHUNTIL M, MOLENAAR MR, SPEE B, et al. Lysosome-mediated degradation of a distinct pool of lipid droplets during hepatic stellate cell activation[J]. J Biol Chem, 2017, 292( 30): 12436- 12448. DOI: 10.1074/jbc.M117.778472.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(5)

Get Citation

PDF

XML

Article Metrics

Article views (261) PDF downloads(40)

Mechanism of microRNA-223-3p inhibiting hepatic stellate cell activation by targeting microtubule-associated protein 1B

DOI: 10.3969/j.issn.1001-5256.2023.12.015

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Mechanism of microRNA-223-3p inhibiting hepatic stellate cell activation by targeting microtubule-associated protein 1B

DOI: 10.3969/j.issn.1001-5256.2023.12.015

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content